header
Image from OpenLibrary

Low dose prolonged infusion gemcitabine and cisplatin versus conventional gemcitabine in patients with advanced bladder cancer : A phase II trial / Kamel Farag Kamel Ahmed Seleem ; Supervised Hussein Mostafa Khaled , Sameh Sayed Ahmed Shamaa , Tarek Nabil Elbolkainy

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Kamel Farag Kamel Ahmed Seleem , 2011Description: 225 P. : charts ; 25cmOther title:
  • دراسة مقارنة بين تأثير الحقن الوريدي البطيء لعقار الجيمسيتابين و الجيمسيتابين بالطرق التقليدية في أورام المثانة المتقدمة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical Summary: Bladder cancer is the most common malignant tumor in Egyptians accounting for 20-30% of all malignant tumors presenting to NCI. Systemic chemotherapy is the only modality that has been shown in phase III trials to improve survival in responding patients with advanced bladder cancer. The gemcitabine-cisplatin combination has proven to be well tolerated and active with overall response rates ranging from 11% to 57%
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2011.Ka.L (Browse shelf(Opens below)) Not for loan 01010110056553000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2011.Ka.L (Browse shelf(Opens below)) 56553.CD Not for loan 01020110056553000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical

Bladder cancer is the most common malignant tumor in Egyptians accounting for 20-30% of all malignant tumors presenting to NCI. Systemic chemotherapy is the only modality that has been shown in phase III trials to improve survival in responding patients with advanced bladder cancer. The gemcitabine-cisplatin combination has proven to be well tolerated and active with overall response rates ranging from 11% to 57%

Issued also as CD

There are no comments on this title.

to post a comment.